Laying the foundation to its immuno-oncology business, Coherus BioSciences has partnered with Shanghai Junshi Biosciences for the development and commercialisation of Junshi’s anti-PD-1 antibody, toripalimab, in the US and Canada. The deal, which is worth up to US$1.8 B, also grants Coherus options to four of Junshi’s oncology assets, including TIGIT-targeted antibody JS006 and IL-2 cytokine JS018. One day after announcing the collaboration, Coherus made an additional US$50 M investment in Junshi.